Teachers Retirement System of The State of Kentucky Sells 19,453 Shares of Repligen Corporation $RGEN

Key Points

• Teachers Retirement System of Kentucky cut its Repligen stake by 16.0%, selling 19,453 shares and leaving it with 101,945 shares worth about $16.7 million (≈0.18% of the company).
• Several large institutions materially increased positions—including Balyasny, Congress Asset Management, Holocene, United Capital and MFS—and overall institutional ownership is 97.64%.
• Analysts show a consensus "Moderate Buy" with a $170.93 target as Repligen recently beat quarterly estimates (EPS $0.49 vs $0.44; revenue $197.9M vs $192.2M) and set FY2026 guidance of $1.93–$2.01 EPS.

Teachers Retirement System of The State of Kentucky reduced its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 16.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 101,945 shares of the biotechnology company's stock after selling 19,453 shares during the quarter. Teachers Retirement System of The State of Kentucky owned about 0.18% of Repligen worth $16,705,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. United Capital Financial Advisors LLC bought a new stake in Repligen during the 3rd quarter valued at $368,387,000. Massachusetts Financial Services Co. MA bought a new position in shares of Repligen in the fourth quarter worth $199,176,000. Balyasny Asset Management L.P. boosted its holdings in shares of Repligen by 390.6% in the third quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company's stock worth $102,557,000 after acquiring an additional 610,837 shares during the period. Congress Asset Management Co. grew its position in shares of Repligen by 241.4% in the fourth quarter. Congress Asset Management Co. now owns 746,306 shares of the biotechnology company's stock valued at $122,290,000 after purchasing an additional 527,714 shares in the last quarter. Finally, Holocene Advisors LP raised its stake in shares of Repligen by 47.0% during the 3rd quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company's stock valued at $184,077,000 after purchasing an additional 440,290 shares during the period. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Roth Mkm started coverage on Repligen in a report on Friday, April 17th. They set a "buy" rating and a $160.00 price objective on the stock. Canaccord Genuity Group reduced their target price on Repligen from $165.00 to $145.00 and set a "hold" rating for the company in a report on Monday, April 20th. Weiss Ratings cut Repligen from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, March 3rd. KeyCorp reissued an "overweight" rating on shares of Repligen in a report on Wednesday, February 25th. Finally, UBS Group cut their price objective on shares of Repligen from $200.00 to $195.00 and set a "buy" rating for the company in a research report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.93.

Repligen Price Performance

NASDAQ:RGEN opened at $117.60 on Monday. Repligen Corporation has a 52-week low of $109.50 and a 52-week high of $175.77. The stock has a fifty day moving average of $123.16 and a 200 day moving average of $145.55. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 8.37. The firm has a market capitalization of $6.63 billion, a price-to-earnings ratio of 138.35, a P/E/G ratio of 2.29 and a beta of 1.19.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The business had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. During the same period in the prior year, the company earned $0.44 EPS. The company's quarterly revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, research analysts expect that Repligen Corporation will post 1.97 EPS for the current fiscal year.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.